Geode Capital Management’s Inhibrx INBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.3M Buy
256,175
+24,666
+11% +$2.47M ﹤0.01% 2037
2026
Q1
$15.6M Buy
231,509
+5,500
+2% +$408K ﹤0.01% 2138
2025
Q4
$17.9M Buy
226,009
+4,089
+2% +$279K ﹤0.01% 2068
2025
Q3
$7.48M Sell
221,920
-4,035
-2% -$99.3K ﹤0.01% 2574
2025
Q2
$3.23M Sell
225,955
-34,074
-13% -$440K ﹤0.01% 2952
2025
Q1
$3.64M Buy
260,029
+4,896
+2% +$66.5K ﹤0.01% 2815
2024
Q4
$3.93M Buy
255,133
+3,914
+2% +$59.6K ﹤0.01% 2858
2024
Q3
$3.93M Buy
251,219
+40,902
+19% +$575K ﹤0.01% 2889
2024
Q2
$2.98M Buy
+210,317
New +$3.29M ﹤0.01% 2982

Other funds holding INBX

Geode Capital Management's INBX Position: Q2 2026 in Review

Geode Capital Management increased its Inhibrx (INBX) stake by 11% in Q2 2026, buying an estimated $2.47M and bringing the position to 256,175 shares worth $24.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2037.

Geode Capital Management first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Geode Capital Management held 256,175 shares of Inhibrx worth $24.3M as of Q2 2026.
  • Geode Capital Management bought 24,666 Inhibrx shares in Q2 2026, an estimated $2.47M.
  • Inhibrx made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2037 holding.
  • Geode Capital Management first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.